Draft:Solvias AG

• Comment: This reads like corporate fluff. Cursory look at earned media shows there is none. Please do not try to re-submit before you can get the company some actual coverage. Superboilles (talk) 17:08, 16 March 2025 (UTC)

---

Solvias AG

Solvias is a global provider of chemistry, manufacturing, and control (CMC) analytical services to the pharmaceutical and biotechnology industries.. Headquartered in Kaiseraugst, Switzerland, the company operates state-of-the-art facilities across France, the Netherlands, and the United States.

History

Solvias spun off from Novartis and was founded in 1999. Initially, Solvias catered to a broad range of clients, including companies in the agricultural, chemical, and food industries, as well as government authorities and research institutes. Over time, Solvias refined its focus, emphasizing catalysis, polymorphism, bioanalytics, and analytical chemistry for the pharmaceutical and biotech industries.

Throughout the 2000s, the therapeutics market experienced a profound transformation driven by technological advancements and the rise of innovative therapies, prompting Solvias to evolve in response. Biologics, such as monoclonal antibodies and recombinant proteins—first introduced in the 1980s—gained significant traction during this time, offering highly targeted treatments for complex diseases. Meanwhile, the advent of cell and gene therapies, ushered in a new era of medicine, holding the promise of potential cures for conditions previously deemed untreatable. As therapeutic modalities became more complex, regulatory agencies worldwide, including the FDA, EMA, and ICH, emphasized the need for robust analytical testing protocols to ensure the quality, safety, and efficacy of products, reflecting a shift toward science- and risk-based approaches in product testing and development. Addressing the growing complexity of the therapeutics market, today Solvias provides an extensive portfolio of analytical services for small molecules, biologics, and cell and gene therapies.

Acquisitions

In February 2013, Solvias acquired Confarma, a company known for its expertise in microbiology, sterility testing, medical device testing, and pharmacopeial analysis methods. This strategic acquisition enabled Solvias to enhance its service offerings and strengthen its market position in the competitive quality control segment, particularly in France, where Confarma had established operations.

In June 2020, Solvias entered a strategic partnership with Water Street Healthcare Partners and JLL Partners to support its global expansion and service diversification.

A year later, in June 2021, Solvias acquired Chemic Laboratories, Inc., a company based in Canton, Massachusetts. This acquisition established a strong foothold in the United States, creating Solvias’ extractables and leachables (E&L) center of excellence in North America.

In March 2022, Archie Cullen was appointed Chief Executive Officer of Solvias, and three months later, in July 2022, Solvias acquired Cergentis, a genomics-focused biotechnology company based in Utrecht, Netherlands. This acquisition bolstered Solvias' platform of biologics and cell and gene therapies testing solutions with TLA, a cross-linking-based technology that, in combination with next-generation sequencing, enables robust detection of all genetic variation, including structural variants, in and around genes of interest and in an allele-specific manner. This technology is particularly valuable for the genetic characterization and quality control of cell lines used in the development of cell and gene therapies.

Services

Solvias provides an array of services designed to support the development of products within highly regulated industries. Core services include:

• Analytical Services: This includes a range of laboratory services such as analytical method development and validation, characterization, cGMP drug substance and drug product testing and release, excipients and raw materials testing, extractables and leachables (E&L), stability studies, biosafety testing, impurity testing and contamination control^[21].
• Biopharmaceutical Analysis: Specialized testing for biologics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), peptides, biosimilars, and other complex biopharmaceuticals^[22].
• Cell and Gene therapies: Specialized testing for biologics, including phase-specific method design, development, transfer, validation and release testing, with particular expertise in cell-based bioassays^[23].

COMMITMENT TO QUALITY AND COMPLIANCE

Solvias is committed to maintaining high standards of quality and regulatory compliance, ensuring that all services adhere to international standards, including Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP).

Solvias undergoes more than 100 customer audits annually, with no critical findings reported in 2023. The company has successfully passed multiple regulatory audits from authorities such as the FDA, EMA, and Swissmedic^[25]. In Switzerland, recent inspections by the FDA in November 2022 and Swissmedic in August 2022 concluded with no critical issues. Similarly, in the United States, the FDA inspection in December 2022 also found no critical issues. In France, an ANSM inspection in September 2022 and an earlier FDA inspection in March 2014 confirmed compliance with regulatory standards. Meanwhile, in the Netherlands, Solvias achieved ISO 17025 certification in August 2022, further attesting to its adherence to international quality benchmarks.

Building on this strong compliance record, Solvias assigns a Qualified Person (QP) to oversee EU batch release. The QP certifies that each batch of medicinal products complies with the EU GMP guidelines, maintaining full regulatory compliance^[25].

Global Presence

Solvias operates globally, providing services to clients in North America, Europe with looking into expansion opportunities in Asia. The company’s headquarters are located in, Kaiseraugst, Switzerland, but it facilities in France, The Netherlands, and two sites in the United States